OSE Pharma and Effimune Announce Proposed Merger to Create Significant Immunotherapy Player
Thursday, February 25, 2016
Orphan Synergy Europe Pharma Sa Merger will result in shareholders of OSE Pharma owning ca. 71 percent of capital of merged entity and shareholders of Effimune 29 percent.
OSE pharma and Effimune announce proposed merger to create significant immunotherapy player.
Source : reuters.com
